SXTP

60 Degrees Pharmaceuticals, Inc.
CAPPED RATING

60 Degrees Pharmaceuticals, Inc. (SXTP) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
B-
Factor Score 3.0 / 5.0
Growth
C
Factor Score 2.2 / 5.0
Profitability
D
Factor Score 1.2 / 5.0
Momentum
D
Factor Score 1.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.1
EV / EBITDA -1.2
Rev Growth YoY -32.5%
Gross Margin N/M
Price Return 3M -52.0%
Price Return 12M -89.5%
Catalyst Signal 0.00
Market Cap $1.8M
TTM Revenue $1.2M
Price / Sales 1.5
ROE -332.9%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B- (3.0) C (2.2) D (1.2) D (1.2) C+ (2.6) C- (2.1)
2026-11-08 B- (3.0) C (2.2) D (1.3) D (1.3) C+ (2.6) C- (2.1)
2026-11-01 B- (3.0) C (2.2) D (1.4) C- (2.0) C+ (2.7) C (2.2)
2026-10-25 B- (3.0) C (2.2) D (1.3) D (1.2) C+ (2.6) C- (2.1)
2026-10-18 B- (3.0) C (2.2) D (1.3) D- (1.1) C+ (2.6) C- (2.0)
Page 1 of 4